Addressing Irreversibility and Structural Distortion in WS2 Inorganic Fullerene-Like Nanoparticles: Effects of Voltage Cutoff Experiments in Beyond Li+-Ion Storage Applications.

Large interlayer spacing beneficially allows Na+- and K+-ion storage in transition-metal dichalcogenide (TMD)-based electrodes, but side reactions and volume change, which pulverize the TMD crystalline structure, are persistent challenges for the utilization of these materials in next-generation devices. This study first determines whether irreversibility due to structural distortion, which results in poor cycling stability, is also apparent in the case of inorganic fullerene-like (IF) tungsten disulfide (WS2) nanocages (WS2IF). To address these problems, this study proposes upper and lower voltage cutoff experiments to limit specific reactions in Na+/WS2IF and K+/WS2IF half-cells. Three-dimensional (3D) differential capacity curves and derived surface plots highlight the continuation of reversible reactions when a high upper cutoff technique is applied, thereby indirectly suggesting restricted structural dissolution. This resulted in improved capacity retention with stable performance and a higher Coulombic efficiency, laying the ground for the use of TMD-based materials beyond Li+-ion storage devices.

Chiral Nanoparticle Chains on Inorganic Nanotube Templates.

Fabrication of chiral assemblies of plasmonic nanoparticles is a highly attractive and challenging task, with promising applications in light emission, detection, and sensing. So far, primarily organic chiral templates have been used for chirality inscription. Despite recent progress in using chiral ionic liquids in synthesis, the use of organic templates significantly limits the variety of nanoparticle preparation techniques. Here, we demonstrate the utilization of seemingly achiral inorganic nanotubes as templates for the chiral assembly of nanoparticles. We show that both metallic and dielectric nanoparticles can be attached to scroll-like chiral edges propagating on the surfaces of WS2 nanotubes. Such assembly can be performed at temperatures as high as 550 °C. This large temperature range significantly widens the portfolio of nanoparticle fabrication techniques, allowing us to demonstrate a variety of chiral nanoparticle assemblies, ranging from metals (Au, Ga), semiconductors (Ge), and compound semiconductors (GaAs) to oxides (WO3).

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).

BACKGROUND: The potential for PPAR agonists to positively affect risk of cardiovascular disease in patients with type 2 diabetes (T2DM) is of persistent attention. The PRESS XII study primarily aimed to evaluate the efficacy and safety of saroglitazar (2 mg and 4 mg) as compared to pioglitazone 30 mg on glycemic control in patients with type 2 diabetes mellitus. METHODS: In this randomized double-blind study, patients with T2DM [glycosylated hemoglobin (HbA1c) ≥ 7.5%] were enrolled from 39 sites in India. Patients received once-daily doses of either saroglitazar or pioglitazone (1:1:1 allocation ratio) for a total of 24 weeks. Patients were continued in a double blind extension period for an additional 32 weeks. Efficacy evaluations of glycemic parameters [HbA1c (Primary endpoint at week 24), FPG and PPG] and other lipid parameters (TG, LDL-C, VLDL-C, HDL-C, TC, Non HDL-C, Apo A1 and Apo B) were conducted at week 12, 24 and 56 and compared to the baseline levels. The efficacy analyses were performed by using paired t-test and ANCOVA model. RESULTS: A total of 1155 patients were enrolled in this study. The baseline characteristics were similar between the three treatment groups. The within group mean (± SD) change in HbA1c (%) from baseline of the saroglitazar (2 mg and 4 mg) and pioglitazone treatment groups at week 24 were: - 1.38 ± 1.99 for saroglitazar 2 mg; - 1.47 ± 1.92 for saroglitazar 4 mg and - 1.41 ± 1.86 for pioglitazone, respectively. Statistically significant reduction from baseline in HbA1c was observed in each treatment group at week 24 with p-value < 0.016. There was a significant reduction in TG, LDL-C, VLDL-C, TC and Non HDL-C with a significant increase in HDL-C from baseline levels (< 0.016). Most of the AE's were 'mild' to 'moderate' in severity and were resolved by the completion of the study. CONCLUSIONS: Saroglitazar effectively improved glycemic control and lipid parameters over 56 weeks in patients of T2DM receiving background metformin therapy and has a promising potential to reduce the cardiovascular risk in T2DM patients. Trial registration CTRI/2015/09/006203, dated 22/09/2015.

Mesoporous Foam TiO2 Nanomaterials for Effective Hydrogen Production.

Hydrolysis of TiCl4 in a diether-functionalized imidazolium ionic liquid (IL), namely 1-methyl-3-[2-(2-methoxy(ethoxy)ethyl]imidazolium methane sulfonate (M(MEE)I⋅CH3 SO3 ), results in a heterostructured organic/inorganic and sponge-like porous TiO2 material. The thermal treatment (300 °C) followed by calcination (500 °C) affords highly porous TiO2 . The characterization of the obtained samples (with and without IL, before and after calcination) by XRD, SEM, and TEM reveals TiO2 anatase crystalline phases and irregular-shaped particles with different porous structures. These hierarchical-structured mesoporous TiO2 nanomaterials were employed as efficient photocatalysts in the water-splitting process, yielding up to 1304 µmol g(-1) on hydrogen production.

Persistent mullerian duct syndrome: A case report and review of the literature.

Persistent mullerian duct syndrome (PMDS) is usually an accidental finding either during orchipexy or during routine inguinal hernia repair in male patients presenting with maldescended or crytorchid testes. It is caused by a defect in the mullerian inhibiting substance system. Intraoperatively, mullerian remnants consisting of an infantile uterus and fallopian tubes are usually found. Familiarity with PMDS is necessary to diagnose the condition. We report a case of PMDS in a 14-year-old male presenting with bilateral undescended testes.